Andrea E. Scaramuzza, Italy
ASST Cremona Ospedale Maggiore PediatricsPresenter of 2 Presentations
3-MONTH EVALUATION OF ADVANCED HYBRID CLOSED-LOOP IN CHILDREN AND ADOLESCENTS WITH TYPE 1 DIABETES: A SINGLE-CENTER EXPERIENCE IN ITALY
Abstract
Background and Aims
The Medtronic Minimed® Advanced Hybrid Closed-Loop system (AHCL) includes an individualised algorithm with optional set points, automated correction bolus, and improved SmartGuard™ Auto Mode stability. After clearing the EU CE Mark in June 2020, it was in the market in Italy starting first week of October 2020. We present the first 3-month results of AHCL in children and adolescents with type 1 diabetes from a single center.
Methods
This one-centre, user-evaluation study in 25 children, adolescents and young adults (aged 1-25yrs), compared AHCL (MiniMed 780G, Medtronic, Northridge, CA, US) automated mode to first 14 days using manual mode, similar to Predictive Low Glucose Management (SAP+PLGM). Time in range (TIR), above range (TAR), below range (TBR), coefficient of variation (CV), mean sensor glucose, GMI, and severe adverse events (severe hypoglicemia and diabetic ketoacidosis in auto vs manual mode are presented.using median and interquartile range (IQR) and compared by Wilcoxon sign-rank test. Median differences and 95%CI were estimated.
Results
Twenty-five patients, 70% males, median age 14y and diabetes duration 11y, were included. Nineteen switched from a hybrid closed-loop system (MimiMed 670G), 4 from multiple daily injections and 2 from other insulin pumps. After 3-month using AHCL, TIR significantly improved and TAR decreased, while TBR did not change; %CV and %GMI significantly decreased (Table).
Conclusions
AHCL (MiniMed 780G system) with automated correction bolus showed a significant improvement in glucose metrics compared to PLGM (manual mode of the system), in children, adolescents and young adults with type 1 diabetes using AHCL after a 3-month usage.